April 13, 2018

Alexion to acquire Swedish biopharma firm in $855M deal

Photo | Contributed
Photo | Contributed
An aerial view of Alexion's New Haven headquarters.

Alexion Pharmaceuticals has inked a deal to acquire a Swedish biopharmaceutical company for $855 million in cash, the New Haven biotech said this week.

The company, Stockholm-based Wilson Therapeutics, is developing a drug to treat Wilson Disease, a rare inherited disorder that prevents the body from eliminating copper properly, causing it to building up in the liver, brain and other organs.

The drug is in Phase 3 clinical trials and has been granted FDA Fast Track status, a designation which speeds the approval process.

"The acquisition of Wilson Therapeutics is a strong strategic fit for Alexion, given the overlap with our current clinical and commercial focus on metabolic and neurological disorders, and is an important step in rebuilding our clinical pipeline," Alexion CEO Ludwig Hantson said in a statement.

Alexion said it is paying for the acquisition with cash on hand. The deal is expected to close in the second quarter of 2018.

Natalie Missakian can be reached at news@newhavenbiz.com

Free E-Newsletter

Sign up now for our New Haven Biz
e-newsletter! Click Here

Subscribe to print for free

Premier issue coming in October. Click here to subscribe

Copyright 2018 New England Business Media